1. Home
  2. PXED vs CRVS Comparison

PXED vs CRVS Comparison

Compare PXED & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PXED

Phoenix Education Partners Inc.

N/A

Current Price

$33.11

Market Cap

1.0B

Sector

Real Estate

ML Signal

N/A

Logo Corvus Pharmaceuticals Inc.

CRVS

Corvus Pharmaceuticals Inc.

HOLD

Current Price

$13.49

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PXED
CRVS
Founded
1976
2014
Country
United States
United States
Employees
3400
37
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.1B
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
PXED
CRVS
Price
$33.11
$13.49
Analyst Decision
Buy
Strong Buy
Analyst Count
7
6
Target Price
$44.29
$30.17
AVG Volume (30 Days)
82.1K
1.3M
Earning Date
04-07-2026
05-07-2026
Dividend Yield
3.07%
N/A
EPS Growth
N/A
48.04
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$3.85
N/A
Revenue Next Year
$4.49
N/A
P/E Ratio
$11.20
N/A
Revenue Growth
N/A
N/A
52 Week Low
$23.52
$3.71
52 Week High
$38.19
$26.95

Technical Indicators

Market Signals
Indicator
PXED
CRVS
Relative Strength Index (RSI) 59.69 55.39
Support Level $28.40 $12.95
Resistance Level $33.05 $14.00
Average True Range (ATR) 1.34 0.68
MACD 0.07 0.28
Stochastic Oscillator 91.44 79.93

Price Performance

Historical Comparison
PXED
CRVS

About PXED Phoenix Education Partners Inc.

Phoenix Education Partners Inc. is a mission-driven organization operating at the forefront of the rapidly evolving post-secondary education market. it is an online education provider and a pioneer in its field. The company benefits from the dynamic interplay between technological innovation, education, employment, and economic trends. It is focused on delivering personalized, career-relevant, and affordable education to its students through its flexible learning model, skills-aligned curriculum, and accessible tuition costs.

About CRVS Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.

Share on Social Networks: